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This study aimed to analyse the outcomes of ultrasound (US) guided radiofrequency ablation (RFA) in patients with renal lesions and to
compare our outcomes with published results of ablations carried out when using computed tomography (CT) guidance. This retrospective
study evaluated RFA of 36 renal tumours in 32 patients (M ¼ 21, F ¼ 11). The mean patient age was 70 years (range, 39e89 years).
Ablations were performed by using either multi-tined applicators or cooled and/or cluster applicators under US guidance. Applicator size
varied from 2e5 cm, depending on the size of the index tumour. Conscious sedation was administered by an anesthetist. Follow-up imaging
by using contrast-enhanced CTwas performed 1, 3, 6, and 12 months after RFA, and yearly thereafter. The mean tumour follow-up time was
12 months (range, 1e35 months). The mean tumour size was 2.7 cm (range, 1e5 cm). Primary effectiveness was achieved in 31 cases
(86.1%), with patients in 5 cases (11.1%) demonstrating residual disease. Three patients had repeated sessions, which were technically
successful. The remaining 2 patients were not re-treated because of patient comorbidities. As a result, secondary effectiveness was achieved
in 34 patients (94.4%). In 1 patient, a new lesion developed in the same kidney but remote from the 2 prior areas of treatment. Hydro-
dissection was performed in 3 patients (8.3%), manipulation or electrode repositioning in 11 patients (30.6%), and ureteric cooling in 1
patient (2.8%). Minor and major complications occurred in 3 (8.3%) and 3 (8.3%) patients, respectively. Correlation coefficients were
calculated for distance from skin to tumour and risk of complication as well as compared with primary and secondary effectiveness. This
study demonstrates that US-guided RFA is an effective treatment for renal lesions, with rates of effectiveness and complication rates
comparable with published CT-guided RFA results.Resume
Cette etude visait a analyser les resultats de l’ablation par radiofrequence (ARF) echoguidee chez des patients porteurs de lesions renales
et a les comparer aux resultats publies sur l’ablation pratiquee sous contro^le tomodensitometrique. Cette etude retrospective a evalue l’ARF
de 36 tumeurs renales malignes chez 32 patients (21 hommes et 11 femmes). L’a^ge moyen des patients etait de 70 ans (entre 39 et 89 ans).
Les ablations ont ete pratiquees au moyen d’electrodes deployables en forme de baleines de parapluie ou d’electrodes refroidies ou triples
refroidies sous contro^le echographique. Le diametre efficace de l’electrode variait de 2 a 5 cm, selon la taille de la tumeur de reference. Les
interventions ont ete pratiquees sous sedo-analgesie (consciente) administree par un anesthesiste. Le suivi des patients a ete realise par
tomodensitometrie avec injection de produit de contraste a un, trois, six et douze mois apres l’ARF, et annuellement par la suite. La periode
de suivi moyenne des tumeurs etait de 12 mois (entre 1 et 35 mois). La taille moyenne de la tumeur etait de 2,7 cm (entre 1 et 5 cm).
L’efficacite primaire a ete atteinte dans 31 cas (86,1%), la presence de cellules tumorales residuelles ayant ete constatee dans 5 cas (11,1%).
Trois de ces cinq patients ont subi des traitements ulterieurs, qui ont ete reussis sur le plan technique. Les deux autres n’ont subi aucun autre
traitement en raison de comorbidites. L’efficacite secondaire a donc ete atteinte chez 34 patients (94,4%). Chez un patient, une nouvelle
lesion s’est developpee dans le me^me rein, mais a distance des deux zones traitees anterieurement. L’hydrodissection a ete pratiquee chez
trois patients (8,3%), la manipulation ou le repositionnement de l’electrode chez 11 patients (30,6%) et le refroidissement ureteral chez un
patient (2,8%). Des complications mineures et majeures sont survenues chez trois patients (8,3%) et trois patients (8,3%) respectivement. Les
coefficients de correlation ont ete calcules pour la distance entre la peau et la tumeur et pour le risque de complications, puis compares avec
les efficacites primaire et secondaire. Cette etude montre que l’ARF sous contro^le echographique est un traitement efficace pour des lesionsDisclosures: The authors have no conflicts of interest to disclose.
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According to the Canadian Cancer Society, 4600 new
cases of renal malignancy were diagnosed in Canada for
2009 (2800 men, 1800 women) [1]. Of all renal cancers, 90%
were renal cell carcinoma (RCC), which accounts for 2%e
3% of all cancers in adults [2e4]. Worldwide, more than
100,000 people die per year from RCC [4]. Therefore, both
current and new treatments must be effective and optimized
to improve patient survival. In North America, staging and
subsequent treatment planning of RCC is most frequently
performed by using computed tomography (CT) as well as
magnetic resonance imaging (MRI) [5,6].
Current treatments for RCCs are generally dictated by the
stage of disease. For early, localized RCC, the spectrum of
therapies includes open or laparoscopic partial or radical
nephrectomy as well as thermal ablation techniques. For
metastatic disease, newer targeted agents, including the use of
tyrosine kinase inhibitors (sunitinib, sorafenib), mammalian
target of rapamycin (mTOR) inhibitors (temsirolimus, ever-
olimus), or anti-vascular endothelial growth factor (anti-
VEGF) agents (bevacizumab) represent the current standard of
care. However, treatment choice depends on additional factors,
including index tumour size and location, coexisting comor-
bidities, renal reserve, previous response to treatment, life
expectancy, and presence of 1 vs 2 functioning kidneys [2,7,8].
Thermal tumour ablation techniques involve inserting an
applicator directly into the tumour and then delivering
radiowaves (radiofrequency ablation [RFA]) or microwaves
(microwave ablation) or by freezing the tumour (cryoa-
blation). Each of these techniques results in protein dena-
turation and coagulation that lead to tumour tissue death [3].
The ablation can be performed intraoperatively or lapa-
roscopically by placing the applicator directly into the
visualized tumour. Alternatively, the RFA electrode can be
inserted percutaneously under image guidance.
Cross-sectional imaging is used not only for tumour detec-
tion and planning but also for monitoring applicator position
during the session and for assessing effectiveness of the abla-
tion at the end of the procedure [9]. Any modality can be used
for these purposes, including ultrasound (US), CT, MRI, and
fluoroscopy, although fluoroscopy is rarely used anymore [9].
Currently, the modality chosen appears to be a matter of
operator preference and institutional availability. In Canada,
consideration of availability, cost, and radiation exposure are
key concerns. However, in the published literature, CT is
currently the most commonly used modality for RFA of
kidney tumours [5,6]. This may be, in part, because of its
accurate imaging of the tumour and surrounding tissueduring needle placement and ability to evaluate efficacy of
the procedure directly after the ablation session [5].
Whereas tumour visualization may be satisfactory in most
cases, the use of CT-guided RFA also results in variable
amounts of radiation exposure to both the patient and the
operator. In addition, it does not allow for real-time needle
placement or procedure monitoring and, in many cases,
requires administration of intravenous contrast agents, which
may be limited in use because of marginal renal function in
this patient subset [5].
US guidance provides a solution to some of these obsta-
cles, because it is often more readily available. Advantages
also include more flexibility with respect to direction of
needle placement, lack of radiation, and lower costs relative
to CT [5]. However, some investigators argue that the loss of
image quality because of acoustic shadowing, especially with
regard to surrounding structures, outweighs these benefits
[5]. In addition, it has been argued that once the procedure
begins, the transient hyperechoic zone, which is created by
the heating in the tissues, limits visualization of the deeper
structures, and adequacy of the ablation margins cannot be
easily determined [10]. In addition, the deeper the lesion, the
lower the US penetration and the worse the image quality.
In Canada, access to CT is more limited than to US, and
the resulting cost of performing the procedure under CT is
more expensive; thus, our centre has performed these RFA
procedures under US guidance. The goal of this study was to
further analyse the benefits and possible drawbacks of using
US guidance vs published results when using CT guidance
for RFA treatment of RCC tumours by comparing their
respective outcomes.
Materials and MethodsPatient and Tumour CharacteristicsPatient and tumour characteristics are presented in Table
1. This retrospective study was approved by our hospital’s
research ethics board to evaluate the outcome of RFA
treatment in patients with renal tumours. There were 32
patients (M ¼ 21, F ¼ 11), with a mean age of 70 years
(range, 39e89 years). Between September 2006 and June
2009, 36 tumours were treated that ranged in size from 1 to
5 cm, with a mean size of 2.7 cm.
As per the Society of Interventional Radiology (SIR)
guidelines, index tumour size was defined as follows: small
tumours (3 cm or smaller), intermediate tumours (3e5 cm),
and large tumours (larger than 5 cm) [9]. Twenty-four of the
tumours (66.7%) in this study were of small size, 10 (27.8%)
Table 1
Patient and renal index tumour characteristics before US-guided radio-
frequency ablation
Patient demographics
No. patients 32
Men, women 21, 11
Mean age (range), y 70 (39e89)
No. tumours 36
Tumour size
Range 1e5 cm
Mean 2.7 cm
<3 cm 24 (66.7%)
3-5 cm 10 (27.8%)
5 cm 2 (5.2%)
Tumour location
Right kidney/left kidney 14 (38.9%)/22 (61.1%)
Upper/mid/lower 5 (13.9%)/16 (44.4%)/15
(41.7%)
Exophytic/parenchymal/central/mixed 20 (55.6%)/13 (36.1%)/0
(0%)/3 (8.3%)
US distance between tumour to skin
Range 2.1e10.9 cm
Mean 6.5 cm
CT distance between tumour to skin
Range 2.6e12.4 cm
Mean 7.7 cm
Parentheses show the percentage of tumours treated.
CT ¼ computed tomography; US ¼ ultrasound.
Table 2
Results from Spearman rho nonparametric correlation analysis that evaluated
complication rates compared with tumour characteristics
Tumour characteristic Correlation coefficient P value
Distance from skin 0.08 .96
Tumour size 0.356 .03a
Tumour location 0.061 .72
a Denotes statistical significance.
Table 3
Results from Spearman rho nonparametric correlation analysis that evaluated
technical failure compared with tumour characteristics
Tumour characteristic Correlation coefficient P value
Distance from skin 0.06 .708
Tumour size 0.457 .005a
Tumour location 0.082 .634
a Denotes statistical significance.
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these 36 tumours, 22 (61.1%) were in the left kidney and 14
(38.9%) were in the right kidney. One patient previously
underwent a radical nephrectomy. Although none of these
tumours were biopsy-proven RCC, their appearance on
cross-sectional imaging with CT and MRI, including lack of
macroscopic fat, presence of enhancement, or a rate of
growth on subsequent imaging, made them suspicious
enough to warrant treatment.
All the patients underwent pre-RFA cross-sectional
imaging with contrast-enhanced CT or MRI. Axial and
coronal reconstructed images were reviewed to determine
size and technical feasibility. Index tumour sizes were
measured with calipers in all 3 dimensions, with the largest
axis used for tumour diameter. Patients were excluded if the
index tumours were >5 cm. Tumours that were very ante-
romedial, completely central, or less than 0.5 cm from the
ureter were also typically excluded because of the known
higher risk of complications.
The location of each tumour was classified as upper,
middle, or lower third and exophytic, parenchymal, central, or
mixed, depending on location. As per the classification of
Gervais et al [11], exophytic tumours are those with >25%
extension into the perirenal fat but not the renal sinus fat [11].
Tumours that extended into the renal sinus fat were classified
as central tumours, which are more technically difficult to
ablate [11]. Parenchymal tumours are those contained within
the renal parenchyma and with no extension into perirenal or
renal sinus fat [11]. Mixed tumours are those that extend into
perirenal and renal sinus fat [11]. In this tumour population,
20 were exophytic, 13 were parenchymal, 0 were central, and
3 were mixed.The distance between the index tumour and the patient’s
skin was also measured. Nonparametric Spearman rho
correlation coefficients were calculated for depth of tumour
from the skin and risk of complications or lack of technical
success. Correlation coefficients of the Spearman rho tests
were also calculated for distance of tumour from skin and
size of the tumour (small, intermediate, large) compared with
risk of complications as well as compared with technical
success (Tables 2 and 3).PlanningAs part of the patient care protocol, within aweek before the
scheduled ablation, a limited abdominal US was completed by
1 of the 2 radiologists (A.K. or D.P.) who perform RFA to
determine the technical feasibility of the procedure and to
determine the best approach. Dimension of the renal lesions
were also measured with calipers in all 3 dimensions and were
compared with the CT and/or MRI results. Risks and benefits
of this technique were discussed with the patient during the
pre-RFA US, which allowed the patient time to make an
informed decision. The patients also underwent blood work,
which included international normalized ratio (INR), partial
thromboplastin time (PTT), platelet level, and creatinine level.TechniqueThe ablations were performed with the patient under
conscious sedation under direct supervision of an anesthe-
siologist. Informed consent was obtained from all the
patients. The procedures were performed by 1 of 2 radiolo-
gists (A.K. or D.P.) who had experience in liver and renal
RFA (3-6 years of experience). All of the procedures were
carried out percutaneously with US guidance (Figure 1).
When RFA was first introduced to our institution, the first 5
patients underwent the procedure by using CT guidance in
conjunction with US. After the first 5 cases, all subsequent
Figure 1. Pre-ultrasoundeguided radiofrequency ablation of renal cell
carcinoma tumour. Ultrasound, coronal.
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patients who were treated solely with US guidance.
An ATL 5000 US unit was used (Philips Healthcare,
Markham, ON) and either a curved (5e8 MHz) US probe or
a linear probe (7e12MHz), depending on patient body habitus
and position of the tumour in the kidneywith respect of the skin
surface. RFA applicator size selection was correlated with
tumour sizewith tips that ranged from2e5 cm. Themajority of
cases (35/36), multi-tined applicators (Boston Scientific Corp,
Natick, MA) were used, with the remaining 1 case in which
cluster applicators were used (Cool Tip, Covidien, Boulder,
CO).
The CTs or MRIs were reviewed before RFA consultation,
and tumours that were close to the bowel or other susceptible
structures were closely evaluated with US before starting the
ablation. If they were within 1 cm of the tumour to be treated,
then the susceptible structures were displaced by hydro-
dissection or manual displacement, or by ureteric cooling with
cool dextrose 5% in water (D5W) in a double J stent placed by
a urologist after consulting the urology service. The type of
displacement performed was at the discretion of the treating
radiologist. The patients were placed supine, oblique, or partly
prone, depending on the location of the tumour. Sterile tech-
nique was used. Two percent lidocaine (Xylocaine) was used
for local anesthesia before insertion of the applicator.Table 4
Outcomes after ultrasound-guided radiofrequency ablation of renal
neoplasms
ComplicationsComplications
Total 6 (16.7%)
Minor 3 (8.3%)
Major 3 (8.3%)
Manipulations
Total 15 (41.7%)
Hydrodissection 3 (8.3%)
Repositioning/manipulation 11 (30.6%)
Ureteric cooling 2 (5.2%)
Local tumour progressions
Total 0 (0%)
Parentheses show the percentage of tumours treated.Complications, both immediate (6e24 hours after abla-
tion), periprocedural (up to 30 days after ablation), and
delayed (30 days or more after ablation), were documented
[9]. Complications were subdivided into minor and major
complications as defined by SIR [9]. Potential minor
complications included minor skin burns, perirenal hema-
tomas, subcutaneous hematomas, hematuria, asymptomatic
pneumothorax, and postprocedural numbness in an affected
dermatome. Potential major complications included second
and third degree burns, hemorrhage that required transfusion,bowel perforation, seeding along the applicator tract, abscess
formation, and ureteric stricture that caused hydronephrosis.Follow-upAfter ablation, the patients were imaged by CT or MRI to
determine technical success, which is defined by SIR as,
‘‘whether the tumor was treated according to protocol and was
covered completely [9].’’ If there was a question of complica-
tions, then a CT was performed within 24 hours of the proce-
dure. Subsequent follow-up unenhanced and contrast-enhanced
CTs orMRIswere performed in all the patients at 1, 3, 6, and 12
months. Additional scans were performed yearly thereafter.
A region of interest was placed over the ablation zone on the
same pre- and postcontrast image to ascertain a lack of
enhancement. The borders of the ablated tumour were
specifically evaluated to ensure that there was no residual rim
of enhancement. A lack of enhancement (<10 Hounsfield
units increase after contrast enhancement) was considered to
represent technically successful ablation. For MRI images,
subtraction images were reviewed (subtracting pregadolinium
images from the nephrographic phase) to determine if there
were any linear or nodular areas of enhancement.Local Tumour ProgressionLocal tumour progression is defined as tumour growth in
an area thought to have been completely treated; this does
not include new foci elsewhere in the organ being treated or
distant metastases [9]. A repeated ablation was performed if
local tumour recurrence was noted after the initial post-RFA
CT. This primary treatment failure has been shown to be
detectable within 3 months after ablation [12].
Results
The results are summarized in Table 4.ManipulationsManipulations were performed in 15 cases (41.7%); 3
patients (8.3%) required hydrodissection (Figure 2, A and B),
Figure 2. Hydrodissection. (A) Ultrasound, coronal dextrose 5% in water
(D5W) infusion during radiofrequency ablation (RFA) (arrows). (B)
Computed tomography, with contrast, axial; fluid layering after D5W infu-
sion (arrowheads); lesion after RFA (arrow).
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repositioning. Ureteric cooling was performed in 2 cases
(5.2%) (Figure 3, A and B). On the pre-RFA CT, the distance
ranged from 2.6e12.4 cm (mean, 7.7 cm). Before the RFA
procedure began, ameasurement was again taken by usingUS,
with distances that ranged from 2.1e10.9 cm (mean, 6.6 cm).ComplicationsFigure 3. Ureteric cooling. (A) Ultrasound (US), coronal; electrode place-
ment close to renal collecting system. (B) US, coronal; renal collecting
system after ureteric cooling.All complications were immediate or periprocedural, within
1 month. Minor complications occurred in 3 cases (8.3%); the
complications included a pneumothorax (Figure 4, AeC),
a second degree skin burn, and a moderate perinephric hema-
toma that stopped spontaneously and did not require transfusion
or other interventions. Two patients (6.2%) had major compli-
cations, including 2 with ureteric stricture with secondary
hydronephrosis (Figure 5, A and B), and an infected hematoma
in1of the2patients aswell (Figure 6,AandB).Althoughpain is
considered an adverse effect and not a complication, it was
reported by 3 of patients (8.3%) in this study.Primary EffectivenessPrimary effectiveness is defined by Goldberg et al [9] as,
‘‘the percentage of tumours that were successfully eradicated
following the initial procedure or a defined course of treat-
ment.’’ Primary effectiveness was achieved in 31 cases
(86.1%), whereas 5 patients (14.9%) showed evidence of
residual disease. Of these patients with residual tumour, 1 had
a central tumour that could not be re-treated. Another patient
declined an additional ablation because of other medical
comorbidities. Three patients (8.3%) required a second
session, which then achieved secondary effectiveness.
Overall, effective treatment was achieved in 34 cases (94.4%).Follow-upPatients were followed up with cross-sectional imaging as
per protocol for a mean of 12 months (range, 1e35 months).
Two patients died of other causes (1 of cardiac failure 2
months after RFA, and the other died of progression of
bladder transitional cell carcinoma [TCC] 1 month later).Local Tumour ProgressionNew disease was demonstrated in 1 case (2.7%) after 12
months. There were no cases of local tumour progression.Statistical AnalysisCorrelations between tumour size and distance of skin
surface to tumour as measured on US images, compared with
Figure 4. Pneumothorax. (A) Computed tomography (CT), without contrast,
axial; pneumothorax in the left upper lobe (arrow). (B) CT, with contrast,
coronal. Tumour after radiofrequency ablation (arrow). (C) Ultrasound, coronal.
Outline of left kidney (arrowheads); renal cell carcinoma lesion (arrow).
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in Tables 3 and 4. The only statistically significant findings
were that larger tumours were associated with increased riskof technical failure and complications. The distance from the
skin to the tumour did not demonstrate a statistically
significant association with technical failure or increased
complication rates.
Discussion
Indications for RFA have been expanding over the past
decade both for intra-abdominal tumours in the liver and
kidneys as well as for certain bone tumours and lung
neoplasms. The use of US-guided RFA for renal lesions is
potentially underused because of the perception of poorer
image quality when compared with CT [9,13].
At our centre, we have been performingUS-guided ablation
because of easier accessibility to US compared with CT. We
retrospectively analysed our own results and then compared
them with published studies by using CT guidance in similar
patient populations. Thus, we were able to perform quality
control to ensure that our technique and treatments are effi-
cacious aswell as provided some evidence to support the use of
US guidance when performing renal RFA.
Use of US-guided RFA is of potential benefit, because US
machines are more widely accessible compared with CT
scanners, the US units cost less and, perhaps most impor-
tantly, US spares the patient and the radiologist from being
exposed to ionizing radiation. The amount of radiation
exposure is potentially increased further when treating
multiple tumours or when complications occur that neces-
sitate repositioning of the RFA applicator and implementa-
tion of various manipulations to avoid damage to adjacent
structure and/or organs.
US guidance is not free of drawbacks. For example, the
gas produced by the ablation can obscure tumour visualiza-
tion and evaluation of technical success [9]. This is less of
a problem when using CT [3]. In some centres, US contrast
agents are used shortly after the RFA to detect the presence
of any residual tumour [14e17]. Although this technique
shows promise, US contrast agents are not available in some
countries. Currently, we do not use this contrast agent at our
institution.
Our comparisons are based on the following parameters:
primary and secondary effectiveness, minor and major
complications, follow-up intervals, and local tumour
progression (Tables 5 and 6) [18e30]. We also calculated the
correlation of distance from skin to tumour and the rate of
complications as well as rates of technical success. CT-
guided studies have reported technical success rates that
ranged widely, from 80%e100%, which is keeping with our
rate of 86.1% [20e30]. This is also similar to other published
studies of US-guided RFA, which have reported their
primary effectiveness rate rates at 86.2%e94.5% [18, 19].
Technical success has been reported to be influenced by
index tumour size, with smaller tumours having better
outcomes than larger tumours [2,13,20,31]. Zagoria et al [13]
found that large tumour size was the only factor that influ-
enced technical success during RFA treatment of RCC
tumours. In our study, 33.3% of tumours were considered
Figure 5. Hydronephrosis. (A) Computed tomography (CT), with contrast, axial; hydronephrosis of the left kidney (arrow) after insertion of a double J stent
(arrowhead). (B) CT, with contrast, coronal; pre-ablation of left kidney, showing renal cell carcinoma lesion (arrowhead); no evidence of hydronephrosis.
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were intermediate in size, ranging from 3.0e4.7 cm.
Another published US-guided RFA study reported that
index tumour size was not an important factor for technical
success; however, a central tumour location did negatively
influence technical success [18]. Their theory was that this
was caused by the ‘‘heat sink effect’’ when heat is conducted
away from the tumour by the surrounding vasculature [3].
In contradistinction, Zagoria et al [13] did not find this to
be a factor. However, central tumours have been associated
with increased risks of complications because of their
proximity to the ureter, although injury to the renal collecting
system has been described as rare [32,33]. Recent pilot
studies have demonstrated that, in appropriately selected
cases, these renal neoplasms can be safely treated with use of
cool D5W infused through the ureter [32]. Although we did
not have a case with a central tumour, we used this technique
with 2 patients who had a deep parenchymal tumour that was
5e7 mm from the ureter. These patients did not develop
a stricture or hydronephrosis after the procedure.
Other manipulations can also be used to try to reduce
complications. Examples include manual displacement or
repositioning, which were used in 11 cases (30.6%) collec-
tively. Hydrodissection, by using D5W, is increasingly being
used to protect surrounding structures, for example, bowel
wall [32]. Hydrodissection was used in 3 cases (8.3%) in our
study. Ureteric cooling was also used in 2 patients for
tumours that were close to the renal collecting system and
calyces.
CT-guided reports have demonstrated complication rates
that ranged from 3.7%-30.4% [20e30]. Our study had minor
complications in 3 cases (8.3%), and major complications in
3 cases (8.3%), for a total of 6 cases (16.7%). This does not
appear to be significantly different from the CT results. Two
other published US-guided studies demonstrated lower rates
of complication, at 11.5% and 5.5% [18, 19].One patient in our study developed a pneumothorax during
the procedure. This was because of a large pulmonary volume
with very deep inspirations. The approach used with this
patient was intercostal, from above, behind the spleen, and the
applicator was placed too high when the patient took a very
deep breath. The pneumothorax was promptly identified after
the ablation and was resolved without any further complica-
tions. The patient was discharged home the next morning,
without requiring a chest tube or any other intervention.
The broad range of complications seen during RFA could
be explained by a number of potential factors, including
tumour location, patient body habitus, distance between
tumour and skin, improper technique or lack of use of
manipulations, and, early on, operator experience. Results
can also be influenced by the ways in which complications
are reported. For example, some investigators do not include
pain as a complication, whereas others do.
Pain is a common adverse effect during RFA and is
somewhat more difficult to quantify retrospectively without
prior use of a visual analog scale and, therefore, more
difficult to report [34]. Also, patients do not always report
pain or they delay reporting until later follow-up visits. Pain
is more intense during the later part of the ablation cycle
[34]. As with all types of pain, tolerance is largely based on
individual pain thresholds, level of anesthesia, and other
comorbidities.
Most patients went home the same day as the RFA, the
majority with only a prescription for Tylenol #3 or Percocet
(oxycodone with paracetamol/acetaminophen) to use as
needed. A few required overnight stays in surgical day care
for pain management or in cases of patients with multiple
other comorbidities, but all the patients were discharged in
the morning. There were no patients admitted to the hospital
for a longer stay.
Patient body habitus can potentially also affect RFA
results, because obesity can make tumour visualization more
Figure 6. Abscess formed from an infected hematoma. (A) Computed
tomography (CT), with contrast, axial. Abscess within left kidney (arrow)
with an air-fluid level (arrowhead). (B) CT, with contrast, axial. Left kidney
after insertion of a pigtail catheter.
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body habitus, it does not account for fat deposition and, thus,
is a less useful predictor for RFA outcome. However, the
distance between the tumour and the skin gives an exact
measurement of fat in the area of interests and was thought to
be a more useful guide in this case. The mean distance was
6.5 cm (range, 2.1e10.5 cm).
By using the Spearman rho test as a nonparametric
correlation, there was no statistically significant correlation
found between the distance from skin to lesion and risk of
complication. The only statistically significant correlation
found when using this test was between tumour size and
complication rates as well as tumour size and technical
failure. This suggests that the suspected limitation of patient
body habitus and use of US may not be as significant as
originally postulated, although the sample size is still rather
small and, therefore, difficult to extrapolate to a general
population.
As with any RCC treatment, there is a risk of local tumour
progression and, thus, follow-up is essential for patientmonitoring. CT-guided studies have reportedmean follow-ups
of 4.9e27.5 months [20e30]. Published local tumour
progression rates for these studies range from 0%e15%
[20e30]. Our mean follow-up time was 12 months (range,
1e35 months). There were no cases of local tumour progres-
sion, but 1 patient developed a new lesion in the lower pole of
the same kidney, which had been ablated for 2 other lesions 12
months previously. Other published US-guided studies
reported local tumour progression rates of 0%e10.3% [18,19].
Long-term follow-up (10 years) is not yet available in the
literature. However, several studies have followed up with
imaging performed at 4 years or more [18e20,35].
Follow-up imaging can be performed with MRI rather
than CT, provided the patient’s creatinine clearance is not
significantly impaired. MRI features of successfully treated
lesions include the following: lack of enhancement, hetero-
geneity, appears hyperintense compared with normal kidney
parenchyma on T1, appears hypointense to normal kidney
parenchyma on T2, a thin rim of peripheral enhancement of
the ablation zone (not visible on CT), perinephric fat
stranding, and possibly fat invagination [36]. These features
are generally similar to CT characteristics, although contrast
resolution of MRI is considered superior to CT, and
subtraction imaging can help to distinguish areas of hemor-
rhage from areas of residual enhancing tumour tissue [36].
This study is limited by the fact that it is a retrospective
study. In addition, most patients did not undergo biopsy for
confirmation of the renal malignancy, although only tumours
that were either very suspicious by CT or MRI criteria or that
were growing over time were subjected to RFA in this series.
It is known that up to 7% of suspicious renal tumours may
represent benign oncocytomas, however, these may be
difficult to diagnose even on a core biopsy [37]. In addition,
we did not routinely measure the creatinine and glomerular
filtration rate after RFA to determine the degree of resultant
impairment of renal function after RFA.
Another limitation of the study was a lack of direct
comparison between US- and CT-guided RFA. A randomized
prospective study that compared both techniques would be
the best way to answer this question. Finally, longer-term
follow-up is required to ascertain efficacy of the US-guided
RFA. There are several CT-guided studies as well as a few
US-guided studies that are demonstrating good intermediate
post-RFA results with follow-up of up to 5 years (Tables 5
and 6). Lastly, the RCC were not all biopsy proven.
Conclusion
Our results are in keeping with the findings of Veltri et al
[18] and support the use of US guidance for RFA of renal
tumours [19]. Compared with CT guidance, we demonstrated
similar results in terms of primary and secondary effective-
ness, minor and major complications, as well as local tumour
progression [7,12,13,20e30]. To our knowledge, no studies
have directly compared the 2 modalities. Prospective studies,
with randomization of patients to receive either CT- or
US- guided procedures should be performed in the future.
Table 6
Comparison of published studies that used computed tomography guided radiofrequency ablation for the treatment of renal cell carcinoma
First author
Publication
Year Journal No. patient/tumours
Mean tumour
size (range), cm Complications
Primary technical
success
Mean
follow-up (mo)
Overall
effectiveness
Zagoria 2007 AJR Am J Roentgenol 104/125 2.7 (0.6e8.8) 8 (8%) overall 109 tumours (87.2%) 13.8 116 tumours (92.8%)
Arzola 2006 Urology 23/27 2.7 (0.9e6.0) 1 minor (3.7%) 16 of 20 (80%) 24 18 of 20 (90%)
Clark 2006 J Vasc Interv Radiol 22/26 2.2 (1.0e4.0) 4 minor (17%) 25 of 26 tumours (96. ) 11.2 25 of 26 tumours (96.2%)
Permpongkosol 2006 J Urol 19/20 2.2 (0.5e4.3) 4 minor (20%) 16 of 20 patients (80% 27.3 (89.5%)
Sabharwal 2006 Cardiovasc Intervent Radiol 11/18 2.0 (1.0e4.3) 1 patient (9.1%) 14 tumours (78%) 10.91 17 tumours (94.4%)
Ahrar 2005 J Vasc Interv Radiol 29/30 3.5 (1.5e6.5) 4 (12%) major; 2 (6.%)
minor; 6 total (18%)
25 patients (83%) 10 23 of 24 patients (95.8%)
Mahnken 2005 Acta Radiol 14/15 3.0 1 major (6.7%); 2 minor
(13.3%); 3 total (20.0%)
15 tumours (100%) 13.9 15 tumours (100%)
Varkarakis 2005 J Urol 46/56 2.2 (1.0e4.0) 1 major (1.8%); 16 minor
(28.6%); 17 total (30.4%)
50 tumours (89.3%) 27.5 53 tumours (94.6%)
Mayo-Smith 2003 AJR Am J Roentgenol 32/38 2.6 (1.0e5.0) 2 minor (5.3%); 1 major
(2.6%); 3 total (7.9%)
26 patients (81.3%) 9 31 patients (96.9%)
Su 2003 Urology 29/35 2.2 (1.0e4.0) 2 major (5.3%); 8 minor
(21.1%); 10 total (26.3%)
33 of 35 (94.3%) 9 11 tumours (85%)
Ogan 2002 Urology 12/13 2.4 (1.4e3.6) 1 minor (7.7%) 13 (100%) 4.9 12 (92.3%)
Parentheses show the percentage of tumours treated.
Table 5
Comparison of published studies when using ultrasound-guided radiofrequency ablation treatment of renal cell carcinoma
First author Publication year Journal No. patient/tumours
Mean tumour
size (range), cm Complications
Prima technical
effect eness, %
Mean
follow-up (mo)
Overall
effectiveness, %
Our series d d 32/36 2.7 (1.0e5.0) 3 major (8.3%); 3 minor
(8.3%); 6 total (16.7%)
86.1 12 94.4
Veltri 2009 Cardiovasc Intervent Radiol 68/87 2.9 (1.3e7.5) 4 major (4.6%); 6 minor
(6.9%); 10 total (11.5%)
86.2 24.4 89.7
Salagierska-Barwinska 2007 Pol J Radiol 55/55 3.6 (1.8e5.9) 3 (5.5%) minor 94.5 25 100
Parentheses show the percentage of tumours treated.
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